- Home
- CIF vs LSTA Comparison
CIF vs LSTA Comparison
Compare CIF & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIF
- LSTA
- Stock Information
- Founded
- CIF 1988
- LSTA 1980
- Country
- CIF United States
- LSTA United States
- Employees
- CIF N/A
- LSTA N/A
- Industry
- CIF Trusts Except Educational Religious and Charitable
- LSTA Misc Health and Biotechnology Services
- Sector
- CIF Finance
- LSTA Health Care
- Exchange
- CIF Nasdaq
- LSTA Nasdaq
- Market Cap
- CIF 30.8M
- LSTA 20.9M
- IPO Year
- CIF N/A
- LSTA N/A
- Fundamental
- Price
- CIF $1.75
- LSTA $2.80
- Analyst Decision
- CIF
- LSTA Strong Buy
- Analyst Count
- CIF 0
- LSTA 1
- Target Price
- CIF N/A
- LSTA $15.00
- AVG Volume (30 Days)
- CIF 43.9K
- LSTA 14.5K
- Earning Date
- CIF 01-01-0001
- LSTA 08-11-2025
- Dividend Yield
- CIF 10.11%
- LSTA N/A
- EPS Growth
- CIF N/A
- LSTA N/A
- EPS
- CIF N/A
- LSTA N/A
- Revenue
- CIF N/A
- LSTA $1,000,000.00
- Revenue This Year
- CIF N/A
- LSTA N/A
- Revenue Next Year
- CIF N/A
- LSTA N/A
- P/E Ratio
- CIF N/A
- LSTA N/A
- Revenue Growth
- CIF N/A
- LSTA N/A
- 52 Week Low
- CIF $1.47
- LSTA $1.87
- 52 Week High
- CIF $1.77
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- CIF 62.33
- LSTA 59.64
- Support Level
- CIF $1.69
- LSTA $2.36
- Resistance Level
- CIF $1.75
- LSTA $2.69
- Average True Range (ATR)
- CIF 0.02
- LSTA 0.22
- MACD
- CIF 0.00
- LSTA 0.02
- Stochastic Oscillator
- CIF 99.67
- LSTA 62.50
About CIF MFS Intermediate High Income Fund
Mfs Intermediate High Income Fund is a United States based diversified closed-end management investment company. Its investment objective is to seek high current income but may also consider capital appreciation. The fund invests a majority of its net assets, including borrowings for investment purposes, in high-income debt instruments. Its portfolio of investments includes investment grade corporate bonds, government securities and other securities.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.